These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 21829017

  • 1. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.
    Kudo M.
    Dig Dis; 2011; 29(3):273-7. PubMed ID: 21829017
    [Abstract] [Full Text] [Related]

  • 2. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
    Zender L, Kubicka S.
    Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
    [Abstract] [Full Text] [Related]

  • 3. Targeted therapy of hepatocellular cancer.
    Wysocki PJ.
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [Abstract] [Full Text] [Related]

  • 4. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Feb; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 5. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M, Ueshima K.
    Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
    [Abstract] [Full Text] [Related]

  • 6. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS.
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
    Kudo M.
    Dig Dis; 2011 Feb; 29(3):289-302. PubMed ID: 21829020
    [Abstract] [Full Text] [Related]

  • 9. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
    Kim HY, Park JW.
    Dig Dis; 2011 Feb; 29(3):303-9. PubMed ID: 21829021
    [Abstract] [Full Text] [Related]

  • 10. Targeted therapy for liver cancer: updated review in 2012.
    Kudo M.
    Curr Cancer Drug Targets; 2012 Nov 01; 12(9):1062-72. PubMed ID: 22920326
    [Abstract] [Full Text] [Related]

  • 11. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
    Lee JM, Han KH.
    Oncology; 2010 Jul 01; 78 Suppl 1():167-71. PubMed ID: 20616600
    [Abstract] [Full Text] [Related]

  • 12. Systemic therapies in hepatocellular carcinoma.
    Wörns MA, Weinmann A, Schuchmann M, Galle PR.
    Dig Dis; 2009 Jul 01; 27(2):175-88. PubMed ID: 19546557
    [Abstract] [Full Text] [Related]

  • 13. Systemic therapy of hepatocellular carcinoma: are we making progress?
    Roxburgh P, Evans TR.
    Adv Ther; 2008 Nov 01; 25(11):1089-104. PubMed ID: 18972075
    [Abstract] [Full Text] [Related]

  • 14. Molecular pathogenesis of hepatocellular carcinoma.
    Cornellà H, Alsinet C, Villanueva A.
    Alcohol Clin Exp Res; 2011 May 01; 35(5):821-5. PubMed ID: 21303380
    [Abstract] [Full Text] [Related]

  • 15. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H.
    Biochem Pharmacol; 2010 Sep 01; 80(5):550-60. PubMed ID: 20371362
    [Abstract] [Full Text] [Related]

  • 16. [Hepatocellular carcinoma].
    Kondo S, Ueno H, Morizane C, Okusaka T.
    Gan To Kagaku Ryoho; 2010 Jul 01; 37(7):1219-23. PubMed ID: 20647702
    [Abstract] [Full Text] [Related]

  • 17. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
    Schulze-Bergkamen H, Fleischer B, Schuchmann M, Weber A, Weinmann A, Krammer PH, Galle PR.
    BMC Cancer; 2006 Oct 02; 6():232. PubMed ID: 17014711
    [Abstract] [Full Text] [Related]

  • 18. Growth factors as therapeutic targets in HCC.
    Furuse J.
    Crit Rev Oncol Hematol; 2008 Jul 02; 67(1):8-15. PubMed ID: 18434184
    [Abstract] [Full Text] [Related]

  • 19. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
    Marquardt JU, Galle PR, Teufel A.
    Dtsch Med Wochenschr; 2012 Apr 02; 137(16):855-60. PubMed ID: 22495921
    [Abstract] [Full Text] [Related]

  • 20. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX.
    Expert Opin Investig Drugs; 2010 May 02; 19(5):663-72. PubMed ID: 20367287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.